News

$GBOX Announces Staggering 800% Increase in 2021 Processing Volume

GreenBox (NASDAQ: GBOX), an emerging and rapidly growing fintech company, has announced preliminary unaudited results for 2021 with a processing record of $1.95 billion in transaction volume, compared to $202 million during the previous year. This represents a staggering increase of over 800% in processing volume, leading to revenues of at least $26.0 million, an over 200% increase when compared to 2020 revenues of $8.5 million. “2020 unquestionably proved our ability to develop and deploy cutting-edge technology. In 2021 we focused on executing on our strategy to build sustainable scale for our products, while adding new leadership team members that will drive our growth plan and establish GreenBox as a world-class brand,” said Fredi Nisan, CEO of GreenBox POS. “There’s a lot of pride around these 2021 results, no doubt. But, make no mistake, we remain laser-focused on molding the future of this company and our determination of becoming the global leader in the digital financial solutions marketplace.”

To view the full press release, visit https://ibn.fm/eCYM0

About GreenBox POS

GreenBox is an emerging financial technology company leveraging proprietary blockchain security to build customized payment solutions. The company’s applications enable an end-to-end suite of turnkey financial products, helping to reduce fraud and improve the efficiency of handling large-scale commercial processing volumes for its merchant clients globally. For more information, please visit the company’s website at www.GreenBoxPOS.com.

NOTE TO INVESTORS: The latest news and updates relating to GBOX are available in the company’s newsroom at http://ibn.fm/GBOX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, January 25th, 2022 News No Comments

$UUUU Much Maligned Uranium Could Save the Planet

January 25, 2022

Freakish Midwest tornados, devastating wildfires, extreme droughts, abnormal floods – all signal the onset of a changing global climate. There’s overwhelming concern about climate change, but it’s difficult to achieve consensus on actions to mitigate it. The COP 26 UN Climate Change Conference last November was a step in the right direction, spurring global commitments and serving a clear notice that the era of coal is rapidly coming to an end. Three dozen countries, including the United States, pledged to stop funding fossil fuel projects abroad by the end of this year, and more than 40 countries promised to phase out coal-fired power, the planet’s most carbon-intensive energy source.

Largely due to capitalism, the shift to renewables is building a real head of steam. However, renewables alone cannot meet global energy needs. Solar and wind provide clean renewable energy when the sun is shining or the wind is blowing, but, if it’s cloudy and calm, they don’t produce much of anything. Since the technology hasn’t been developed to easily and cheaply store electricity in large quantities, other energy sources must fill this intermittency gap. Without 24/7 base-load producers, there currently isn’t enough consistent uninterrupted energy to sufficiently supply the grid, no matter how many solar or wind facilities get tacked on.

Excluding fossil fuels, there’s currently only one real viable option for reliable 24/7 base-load electricity – nuclear power. Clean, safe and affordable, nuclear power is the only known low-carbon reliable power source that can meet both current and future base-load electricity demands while reducing air pollution and mitigating climate change. U.S. nuclear power plants already generate nearly 20% of the U.S.’s electricity and 55% of its carbon‐free electricity.

Nuclear power requires use of U3O8, the most stable form of uranium oxide. It is commonly found in nature, but extraction is only economically viable from rich deposits. The largest producer of uranium in the U.S. is Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR).

The leading U.S. diversified uranium miner, Energy Fuels is also the country’s leading conventional producer of vanadium and, importantly, began production of rare earths in 2021 at a stage more advanced than any other U.S. company. These are all designated as critical minerals by the U.S. government for national security as well as economic growth and stability.

Energy Fuels’ uranium production portfolio stands apart in the world. The company has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and are uniquely positioned to increase production to meet new demand – and demand is expected to surge along with uptake.

There are substantial direct drivers to increased uranium demand. Nuclear already provides a large portion of the nation’s electricity, and any real increase in electricity demand would require significant new nuclear capacity. It’s also the only known clean, safe, reliable base-load provider of carbon-free electricity in the transition to renewables. In addition and of substantial note, China is planning at least 150 new nuclear reactors in the next 15 years and has started building its first small modular reactor (“SMR”). Small modular reactors represent a new approach and could change the landscape of nuclear power.

This “new generation of nuclear reactors could hold the key to a green future”, as heralded and headlined in a recent Time magazine article. Current nuclear power plants run most efficiently at full blast, which makes it difficult to adapt to a grid increasingly powered by variable sources (again, not every day is sunny or windy). This next generation of nuclear technology will be more flexible, able to adapt and respond quickly to the ups, downs and intermittency in supply and demand. The new generation of reactors differentiate from old-school reactors in size, scale, approach, safety, and application.

With few operators in the space, the technology and opportunity have attracted notable interest and financial backing from Silicon Valley, Bill Gates, and the U.S. Department of Energy. Smaller reactors could be built in factories, ensuring quality control, and deployed to remote locations that lack wind, sun or other resources for energy production. They also can be purpose built to need, customized for use, and easily scaled. This exciting new technology to achieve carbon-free energy has potential to supplement other energy sources or even become a dominant method of energy production. Uranium demand should increase in lock step as the technology scales.

In its annual long-term analysis on the future of the energy economy, BloombergNEF outlines three climate scenarios that achieve net-zero emissions by 2050. Each of Bloomberg’s scenarios describe major transformations in the primary energy supply, and nuclear remains a critical portion of all three scenarios. In the scenario that reduces fossil fuel use the most, nuclear makes up a whopping 66% of primary energy in 2050, compared with 5% today.

This all adds up to a nuclear power renaissance, and demand for uranium is likely to remain unabated as the entire world continues to decarbonize. Much maligned uranium could be what ultimately saves the planet.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire 

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Tuesday, January 25th, 2022 News No Comments

$UUUU Uranium’s Bull Run Triggers Investment in Exploration

January 25, 2022

The exploration budgets of uranium companies had been steadily declining since 2011, but the recent rosy outlook of the metal has caused a reversal of this trend. According to S&P Global Capital, exploration budgets for uranium increased by 10.7% year-on-year in 2021. When that increase is broken down by country, Canada emerges as the leader of the pack with an investment of $67 million being budgeted for exploratory work by Canadian-based companies. The United States comes in second with $10.1 million earmarked for uranium exploration.

While these exploration budgets recorded in 2021 are a far cry from the massive investment sunk into exploring for uranium as the 2000s came to an end, the fact that money is being set aside for exploration is good news, since this is an industry that had fallen out of favor. The recent price increases also paint an encouraging picture of yellowcake. The metal surged from its lows of approximately $20 per lb. recorded in 2017–2018, and now it is trading at more than double that price.

This price rally has been helped by three key factors. First, Sprott, a Canada-based investment fund, went on a buying spree. This action woke up the sector to the potential of the metal in the years to come. Secondly, the ongoing unrest in Kazakhstan, the leading producer of uranium globally, has led to concerns about the ability of the country to supply uranium in the same quantities that it has in the past. Alternative sources are being looked for.

The other big factor that is supporting the yellowcake rally is the climate conference held recently in Glasgow. COP26 emphasized the urgent need to switch away from “dirty energy” such as coal in favor of cleaner forms of energy, including solar energy, nuclear energy, hydro energy and wind energy. A number of EU nations have even put nuclear energy at the center of their plans to hit their net-zero targets, and this is undoubtedly causing the ripples within the nuclear energy sector that have generated added interest in the stocks of uranium extraction companies, including Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR).

However, the increased interest in exploring for uranium is unlikely to result in many exploration projects being taken all the way to production. Analysts say that for this to happen, the price of the metal has to rise above the $50 mark in order to justify the huge expenditure needed to bring a mine to production. What is most likely to happen is that preexisting mines that had been mothballed will be reactivated, and with time, new sites will also come online as the rally continues to a level that can sustain the heavy investment that goes into opening a new mine.

NOTE TO INVESTORS: The latest news and updates relating to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire 

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Tuesday, January 25th, 2022 News No Comments

$IWBB CEO Featured in The Daily Helping Podcast Interview

Tingo Inc. (OTC: IWBB) founder and CEO Dozy Mmobuosi was featured in a recent interview on The Daily Helping Podcast, a series focused on providing food for the brain, knowledge from the experts and tools to win at life. Hosted by entrepreneur and philanthropist Dr. Richard Shuster, the broadcast is available for on-demand listening on The Daily Helping. During the interview, Mmobuosi discussed his background in business leading up to the founding of Tingo as a way to provide agribusiness owners access to information and financial services. “We needed to create a niche market, because we didn’t have the resources to compete with Samsung and Nokia and the big brands at that time. I looked at various sectors and realized that the sector that needed all the help via technology was agribusiness,” Mmobuosi said. “Millions of undocumented agribusiness owners did not have a single bank branch in their village. It was clear that we must bring financial services to the rural communities of Nigeria. The fastest way to deploy services is through technology. We knew that the first thing to do was to make smartphones available to these farmers. We set up assembly lines in Abuja and Lagos. We made sure that each of these devices was preloaded with our mobile wallet, which these farmers would use to do their transactions.”

To view the full press release, visit https://ibn.fm/41566

About Tingo Inc.

Tingo is a unique agri-fintech company using smartphones to deliver a marketplace that enables 10 million subscribers to manage their commercial activities of growing and selling their products to market participants. The ecosystem provides a one-stop-shop solution to enable subscribers to manage everything from airtime top-ups, bill pay services for utilities and other service providers to access to insurance services and microfinance to support their value chain from seed to sale. Tingo has two innovative platforms: Nwassa, Africa’s first digital agriculture ecosystem, and Tingo Pay, a mobile payment gateway. Tingo International Holdings is a majority shareholder in Tingo Inc., which owns 100% of Tingo Mobile PLC in Nigeria. For more information, visit the company’s website at www.TingoInc.com.

NOTE TO INVESTORS: The latest news and updates relating to IWBB are available in the company’s newsroom at http://ibn.fm/IWBB

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, January 25th, 2022 News No Comments

$CNSP Marks Significant Milestone in Pursuit of Berubicin Approval for Global GBM Treatment, Raises $11.5 Million from Private Placement

January 25, 2022

  • CNS Pharmaceuticals received approval from swissethics for its potentially pivotal study of Berubicin, a novel anthracycline for the treatment of Glioblastoma Multiforme (“GBM”)
  • The approval is the first from a European Ethics Committee
  • The company, which dosed the first patients in its Berubicin program in September, has selected multiple clinical sites across the U.S., Spain, France, Italy, and Switzerland
  • CNS recently closed an $11.5 million private placement
  • It intends to use the net proceeds to fund its clinical trials and preclinical programs, other R&D programs, and for general corporate purposes

Clinical stage biotechnology company CNS Pharmaceuticals (NASDAQ: CNSP) is celebrating a significant milestone as it journeys toward its potentially pivotal study of Berubicin for the treatment of Glioblastoma Multiforme (“GBM”). The company announced December 2 that it had received approval from swissethics, the umbrella organization of the cantonal Ethics Committees in Switzerland (https://ibn.fm/NisfL).

The first from a European Ethics Committee, the approval partly fulfills CNS’s goal of seeing Berubicin approved for the potential treatment of GBM globally. “This terrible disease does not discriminate on the basis of geography or anything else: Patients in Europe are as desperate as patients in the United States, and treating patients is not only why we do what we do, but how we do it as well. Driving patient enrollment is how we advance Berubicin’s development, and opening additional clinical sites around the globe is the pivotal piece that allows us to ramp up our efforts and move toward data,” stated CNC Pharmaceuticals CEO John Climaco.

So far, the company has selected tens of clinical sites across the United States, Spain, France, Italy, and Switzerland. In addition, CNS has already dosed the first patients in its Berubicin clinical development program, with a September 30, 2021 announcement noting that additional patient enrollment, randomization, and dosing was well underway in the United States (https://ibn.fm/qI7q2).

Berubicin mid last year received the U.S. Food and Drug Administration (“FDA”) Fast Track Designation as well as an Orphan Drug Designation (https://ibn.fm/PSSiU). Notably, the former designation helps facilitate the development and expedited review of drugs with the potential of treating serious conditions with high unmet medical needs, thereby underlining the seriousness of GBM, one of the most aggressive, deadly, and treatment-resistant cancers that form in the brain.

While chemotherapy medications are usually prescribed to patients living with the condition, results are underwhelming, if not devastating. According to CNS, the current standard of care is ineffective in about 60% of patients.

GBM is the most common malignant brain and central nervous system tumor accounting for 47.7% of all cases, according to data from the American Association of Neurological Surgeons (“AANS”). Its prevalence within a population of 100,000 people stands at 3.21. But despite this low incidence rate, the disease is lethal – only 40% of patients survive in the first year after diagnosis and 17% in the second year. Moreover, it can cause death in six months or less (https://ibn.fm/wU6vY).

In this regard, the recent approval, as well as CNS’s dosing efforts, offer a robust foundation for a potentially pivotal global trial.

The adaptive, multicenter, open-level, randomized, and controlled study will evaluate Berubicin in adult patients with recurrent GBM (WHO Grade IV) after failure of standard first-line therapy. About 243 patients with GBM after failure of standard first-line therapy will be randomized in a 2:1 ratio to receive Berubicin or lomustine, a chemotherapy drug, in order to evaluate overall survival, the primary endpoint of the study.

It is noteworthy that Berubicin is the first anthracycline to cross the blood-brain barrier. It evidences effectiveness in treating GBM. “[Anthracycline] is a classic drug that’s been around for 60 years. It’s the first line therapeutic for all sorts of difficult-to-treat cancers. But no one has been able to get a drug like this across the blood-brain barrier until our Founder modified the classic anthracycline molecule to be more effective in crossing the blood-brain barrier,” said Climaco during an October interview with Proactive (https://ibn.fm/EJjMb).

Meanwhile, CNS Pharmaceuticals recently closed a previously announced private placement, priced at-the-market under Nasdaq rules, of over 12,105,264 shares of common stock (or pre-funded warrants in lieu thereof), raising gross proceeds of $11.5 million (before deductions). CNS intends to use the net proceeds to fund its clinical trials and preclinical programs, other R&D operations, and for general corporate purposes (https://ibn.fm/aTRJE).

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Tuesday, January 25th, 2022 News No Comments

$SVFD Announces Partnership with Israel’s Second Largest Exporter of Fresh Produce

Save Foods (NASDAQ: SVFD), an agri-food tech company specializing in eco crop protection designed to reduce food waste and ensure food safety, has completed several successful trials with Galilee Export, the second largest exporter of fruit and vegetables in Israel. As a result of the trials, effective immediately Galilee Export will be requiring all its bell pepper suppliers to use Save Foods’ treatment; Galilee Export noted that it plans to start using the treatments on avocados as well. According to the announcement, Galilee Export has been evaluating Save Foods’ treatment for several months and has seen a reduction in decay and food waste as well as an improvement regarding the firmness of peppers. The company is hoping to extend its market reach to countries with stricter pesticide regulations as well as evaluate using the treatment on other fruits and vegetables. “Our products address two of the major challenges of the food industry — food waste and loss reduction,” said Safe Foods CEO Dan Sztybel in the press release. “Packing houses around the world are facing new challenges, such as keeping produce fresh throughout the often long transportation and distribution process, and maintaining quality and shelf life with significantly reduced pesticide levels. Many major packing houses are currently carrying out trials on our products. We are looking forward to working with Galilee Export and are confident that we will be adding more major clients to our portfolio soon.”

To view the full press release, visit https://ibn.fm/3mSzO

About Save Foods Inc.

Save Foods is an Israel-based, agri-food tech company that addresses two of the most significant challenges in the fresh-produce industry: food waste and loss, and food safety. The company is dedicated to delivering cost-effect, easy-to-implement solutions for improved safety, freshness and quality every step of the way from field to fork, allowing stakeholders along the food chain to reclaim produce that would otherwise have gone to waste. Collaborating closely with its customers, Save Foods develops technology that benefits the entire supply chain and improves the safety and quality of life of both workers and consumers. SVFD’s initial applications are in post-harvest treatments in fruit and vegetable packing houses processing citrus, avocado, pears, bell peppers and mangos. By controlling and preventing pathogen contamination and significantly reducing the use of hazardous chemicals and their residues, Save Foods’ eco treatments not only prolong the shelf life of fresh produce shelf life and reduces food loss and waste, but they also help to ensure a safe-to-consume end product. For more information about the company, visit www.SaveFoods.co.

NOTE TO INVESTORS: The latest news and updates relating to SVFD are available in the company’s newsroom at http://ibn.fm/SVFD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Monday, January 24th, 2022 News No Comments

$RWBYF 420 with CNW – SAFE Banking Act Sponsor Vows to See Bill Passed Before He Retires

January 24, 2022

Operating in the legal cannabis space is no mean feat. Due to the plant’s federal status as a controlled substance, marijuana businesses have to deal with a lot of issues that players in other industries don’t even have to think of. For starters, most banks refuse to work with marijuana businesses in fear of federal reprisals, forcing the businesses to operate on a largely cash-only basis. This makes accounting and filing taxes extremely cumbersome and makes the business prime targets for criminals.

For quite a while, industry stakeholders have argued for some kind of policy or regulation that would allow these companies access banking services. The only lawmaker who heeded the call was Rep. Ed Perlmutter, who introduced the Secure and Fair Enforcement (“SAFE”) Banking Act to the House of Representatives in March 2019. The legislation would prohibit federal banking regulators from penalizing banks that provided financial services to legal cannabis businesses. Despite the potential benefits it could provide to the industry, the SAFE Banking Act did not gain the traction it needed to advance.

While the House has approved some form of the SAFE Banking Act, it failed to advance past the Senate in any form even when the Democrats had majority votes. Perlmutter, who recently announced that he would be retiring from Congress come next election, says this has left him “pretty irritated.” Senate Majority Leader Chuck Schumer has consistently stood in the way of his bipartisan legislation. Schumer has been working on a federal legalization bill with federal lawmakers for some time now, and he does not want banking legislation before comprehensive cannabis reform is enacted.

With Perlmutter now in his final days as a lawmaker, he says he will use his remaining time to push the SAFE Banking Act and see get it approved. He “absolutely” believes that if the bill lands on President Joe Biden’s desk, the president will sign it into law. Forty-seven states now have some kind of marijuana market, he says, and this greatly underscores the need for “legitimate banking services.” So although he’s a frustrated with the SAFE Banking Act’s lack of progress, Perlmutter believes that the bill’s passage is a “no brainer.”

He plans on playing a major role in helping to establish cannabis banking and hopes legislators will be able to get the bill through the senate and onto the president’s desk by the end of the year. If this law were to be enacted, cannabis sector players such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) would have one less regulatory hurdle to face in their bid to expand their operations and address the needs of more consumers.

NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Monday, January 24th, 2022 News No Comments

$NMRD Commence Rollout of Their Miboko Application; Company Targets Employers & Insurers to Ensure Broad Commercial Distribution

January 24, 2022

  • Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
  • The company recently announced the rollout of its Miboko application by targeting insurers and employers
  • In 2019, over $760 billion was spent on diabetes-related health care, equating to $9,000 per diabetic patient compared to $1,600 for a non-diabetic individual
  • The Miboko application provides users with an efficient and accurate means of tracking their day-to-day glycaemic levels, a key determinant of overall metabolic health

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced that it would launch Miboko, the company’s new metabolic health program using a non-invasive glucose sensor, for the use of employers and insurers worldwide. Nemaura Medical aims to promote the broad penetration and adoption of the Miboko device as a form of preventative medicine for a broad user base. The company opts to pursue the above commercial distribution channels to ensure the device’s successful rollout and adoption (https://ibn.fm/Yd5xE).

Over 420 million people globally are currently living with diabetes, with prediabetic cases totalling almost three times that number. Meanwhile, and in the US alone, over $760 billion was spent on diabetes-related health care expenditures during 2019, equating to an average annual spend upwards of $9,000 per diabetic patient compared to approximately $1,600 for a healthy individual (https://ibn.fm/HCUgW).

The Miboko application, a service offering that has been in development over the past 18 months, uses a non-invasive glucose sensor to measure and monitor users’ blood sugar levels, which are based on glucose tolerance or insulin resistance. The device is then linked to an AI mobile application, which seeks to provide users with personalized information by tracking their metabolism. Users will be able to find out how well their body responds to sugar through their metabolic health score — and how what they eat and what they do every day uniquely affects their metabolic health.

Nemaura Medical believes the Miboko application could address a significant mass-market opportunity, benefitting roughly a third to half of the global population. The human body’s ability to metabolize sugar has been a key influential factor in determining one’s appetite, weight, sleep quality, and energy and mood levels and even plays a critical factor in chronic diseases (beyond just diabetes) like heart disease and dementia.

“Introducing Miboko to the population at-large through employers and insurers will allow Nemaura to reach a much wider audience in a much faster fashion than solely relying on a direct-to-consumer campaign, and in the Western world, these institutions are the most reliable gateway toward wider adoption of preventative health maintenance practices,” commented Nemaura CEO Dr. Faz Chowdhury.

In addition to following their day-to-day metabolic health on the application, Miboko users will also receive weekly and monthly reports that show and explain their body’s unique metabolic health score whilst providing a breakdown of how each of their habits impacts their overall health and wellbeing.

Historically, diabetic and near-diabetic patients have monitored their blood sugar levels by collecting blood capillary samples, which have subsequently been analyzed by an accredited laboratory (https://ibn.fm/zIK2Z). Through the launch of the Miboko application, Nemaura Medical has sought to democratize access to blood sugar testing, enabling millions of individuals around the world to quickly, accurately and painlessly track their glycaemic levels – a significant step towards ensuring their long-term health.

For more information, visit the company websites at www.NemauraMedical.com. For more information on Miboko, visit www.Miboko.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Monday, January 24th, 2022 News No Comments

$GCAC Cepton Technologies Inc. Merger to Be Discussed at Upcoming Investor Day

Growth Capital Acquisition Corp. (NASDAQ: GCAC), a publicly traded special purpose acquisition company, and its upcoming merger with Cepton Technologies Inc., a Silicon Valley innovator and leader in high performance MMT(R) lidar solutions, will be the focus of a virtual investor day event. The event is scheduled for Thursday, Jan. 27, 2022, at 12 p.m. ET. The event will be hosted by Cepton management and will include a discussion about recent industry trends as well as an update regarding the pending transaction. The webinar will be broadcast live with a replay available on the company website following the event. The two companies entered into a definitive merger agreement in August 2021 that expected to close in Q1 2022; the combined company will be named Cepton Inc., with the expectation that shares will be traded on the Nasdaq stock exchange under the ticker symbol CPTN. Cepton has developed a patented Micro Motion Technology, known as MMT(R), which is designed take lidar mainstream and achieve a balanced approach to performance, cost and reliability while enabling scalable and intelligent 3D perception solutions across industries.

To view the event, visit https://ibn.fm/tNsuM

To view the full press release, visit https://ibn.fm/hfhF1

About Growth Capital Acquisition Corp.

GCAC is a Delaware blank check company, also commonly referred to as a special purpose acquisition company (“SPAC”), formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities in any industry or geographic region. GCAC is led by its co-CEOs Akis Tsirigakis and George Syllantavos. For more information about the company, visit www.GCACorp.com.

NOTE TO INVESTORS: The latest news and updates relating to GCAC are available in the company’s newsroom at http://ibn.fm/GCAC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Monday, January 24th, 2022 News No Comments

$FLGC Appoints Renowned Genetics, Cultivation Expert as Advisor

Flora Growth’s (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has named Derek Pedro, an industry-leading cannabis genetics and cultivation expert, as an advisor. Pedro is recognized as a pioneer in the cannabis industry and has consulted on cannabis genetic and cultivation projects around the world, including Canada, the United States, Latin America, Europe and China. In his role at FLGC, he will focus on developing the company’s current register of high-THC and high-CBD strains. The company hopes to offer cannabis flower offerings that are uniquely Colombian to both domestic and international markets. Flora Growth is committed to increasing its cannabis production, and Pedro’s appointment is seen as a way to support the company’s continued adaptation of proven genetics to the unique Colombian climate at one of the lowest cost bases in the world. With more than three decades of experience, Pedro has developed and cultivated hundreds of strains with more than 50 being commercialized within the legal Canadian market; his high-THC strain, called Pedro’s Sweet Sativa, was named top sativa flower in Canada by King Magazine. “As an internationally recognized industry expert and innovative cultivator, the appointment of Derek Pedro aligns perfectly with our goals to optimize our expanding Cosechemos facility operations and increase our varietal offering of cannabis flowers,” said Flora Growth president and CEO Luis Merchan in the press release. “Mr. Pedro has a well-earned reputation as one of the world’s leading experts on cannabis cultivation, and we are thrilled to have him join us as we develop our growing portfolio of brands and expand our global distribution.”

To view the full press release, visit https://ibn.fm/1mwso

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands that delivers the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. For more information about the company, please visit www.FloraGrowth.ca.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at http://ibn.fm/FLGC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Monday, January 24th, 2022 News No Comments

$FLGC Kicks off 2022 with Successful First Cannabis Extraction at new Colombia Facility, the Appointment of Tim Leslie as Advisory Board Chairman, and 360 Financial Inc.’s FLGC stock purchase

January 24, 2022

  • Flora Growth just announced the production of its first batch of crude oil through its newly constructed facility in Colombia
  • The company has also initiated the EU-GMP certification process that will allow it to target international medical cannabis markets
  • Flora Growth also announced the appointment of Tim Leslie as Chairman of its newly established Advisory Board
  • Leslie will play a key role in advising the company on how best to navigate the regulatory framework of building a truly global company
  • 360 Financial, Inc. announced the purchase of 13,162 Flora Growth shares as of Q4 2021

Flora Growth (NASDAQ: FLGC) set out to increase sales and grow its market share for the 2022 calendar year, intending to assert its position as a leader in the global CBD sector. Barely a month into the new year, it has already achieved some key milestones that only offer a glimpse into the scale at which this company plans to operate for the rest year.

On January 11, Flora Growth announced the production of its first batch of crude oil through its newly constructed extraction facility in Colombia. This was achieved through Cosechemos, a wholly-owned subsidiary that also initiated the process to become EU-GMP certified (https://cnw.fm/kYnSg).

In December 2021, Cosechemos successfully extracted the first batch of High-THC crude oil. It later submitted it to the Colombian Government per the requirements for obtaining Flora’s 2022 quota for THC derivatives. This showed the facility’s capacity and potential to serve as a primary processing hub for Flora Growth. So far, it is equipped to facilitate both drying and processing of all the company’s cultivated flower into finished, packaged dry flower and extracted material that is then sold domestically, in Colombia, and exported to wholesale cannabis markets abroad.

“Global cannabis markets are growing at an incredible rate, and Flora is ready to meet that demand for cannabis-derivatives with the completion of our new EU-GMP compliant extraction facility in Colombia,” noted Luis Merchan, the President and Chief Executive Officer (“CEO”) of Flora Growth.

With the completion of the EU-GMP certification, coupled with Flora’s recent Good Agricultural and Collection Practices (“GACP”) certification, the company will be poised to target the international medical cannabis markets. The goal is to disrupt this industry globally, leveraging its cost advantage given that its outdoor-cultivated cannabis is grown at as little as 6 cents per gram.

“This is another major step for Flora Growth, as we are now in a position to seek EU-GMP certification, with the ultimate goal of disrupting the global cannabis derivatives market with our low-cost product,” noted Mr. Merchan.

“Further, the completion of the facility immediately allows us to supply extracts and derivatives to our CPG portfolio, including Flora Beauty and Kasa brands, unlocking additional cost efficiencies,” he added.

Jason Warnock, the Chief Research Officer (“CRO”) of Flora Growth, is confident that this new Colombia facility will have long-term benefits given the potential that the cannabis derivatives market currently has. He is also optimistic that it will help increase the range of the company’s products for a growing international medical market.

Flora Growth also recently established an Advisory Board in a move that seeks to develop the company’s corporate structure and include a robust roster of human capital. Its most recent addition to this Board is Tim Leslie, an accomplished business leader, and cannabis industry expert, who will now serve as its Chairman (https://cnw.fm/FCdk3).

Mr. Leslie will lend over two decades of experience working at Amazon and his law educational background from Yale. He has made a name for himself working with scaling companies, building and managing Amazon’s international legal team, and even overseeing the global launch of Amazon Prime Video. Mr. Leslie has also served as the CEO of Leafly, one of the world’s most authoritative digital cannabis data sources. He has also been on the board of various renowned cannabis companies.

“We are pleased and honored to have Tim join us as the first Chairman of our Advisory Board,” noted Mr. Merchan.

“We will look to our newly established Advisory Board for counsel on how to amplify our growth opportunities both domestically and internationally. Tim will play a key role in advising on how best to navigate the regulatory framework of building a truly global company, something he specifically worked on in his time at Amazon,” he added.

Mr. Leslie expressed his excitement following his appointment, citing Flora’s prospects that current clinical trials at the University of Manchester and in the United States can develop new, safe, plant-based medications to treat various conditions, including brain health pain and fibromyalgia. He acknowledged that the type of international growth Flora Growth is aiming for could prove difficult, but he has the experience given where he has worked before.

“I hope to leverage that knowledge to assist the Flora team in making sound strategic decisions that will fuel Flora’s growth on an international scale,” he noted. “I truly believe in the potential of the cannabis industry to improve health, welfare and longevity of people around the globe. I feel that I have found the right fit in supporting this organization,” he added.

Mr. Leslie also serves as an Executive in Residence at Beloit College and sits at the Board of Advisors of Endocanna Health and New Frontier Data.

Additionally, investment company 360 Financial, Inc. recently announced owning 92 stocks with a total value of $219 million as of the last quarter of the 2021 financial year. Among the new purchases were 13,162 shares of Flora Growth, at a purchase price between $1.7 and $5.68 and an estimated average price of $3.44. The impact to the portfolio following this purchase was 0.01% (https://cnw.fm/fZdOb).

For more information, visit the company’s website at www.FloraGrowth.com.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Monday, January 24th, 2022 News No Comments

$ANPC Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

PHILADELPHIA, Jan. 24, 2022 — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, announced today that it has received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) dated January 19, 2022 indicating that the Company is not in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) set forth in the Nasdaq Rules for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5450(b)(2)(C) requires companies to maintain a minimum MVPHS of US$15 million, and Listing Rule 5810(c)(3)(D) provides that a failure to meet the MVPHS requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the MVPHS of the Company for the 30 consecutive business days from December 3, 2021 to January 18, 2022, the Company no longer meets the MVPHS minimum requirement. This notification does not impact the listing and trading of the Company’s securities at this time.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(D), the Company has a compliance period of 180 calendar days (or until July 18, 2022) to regain compliance. If at any time during this compliance period the Company’s MVPHS closes at US$15 million or more for a minimum of ten consecutive business days, Nasdaq will notify the Company that it has achieved compliance with the MVPHS requirement, and the MVPHS matter will be closed.

In the event the Company does not regain compliance with Rule 5450(b)(2)(C) prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. Alternatively, the Company may consider applying to transfer its securities to the Nasdaq Capital Market.

As previously announced, the Company also has a separate Nasdaq Global Market deficiency in the requirement that it maintain a minimum Market Value of Listed Securities (“MVLS”) of US$50 million. The Company has until March 23, 2022 to regain compliance with the MVLS requirement. Resolving the MVPHS deficiency will not automatically resolve the MVLS deficiency and vice versa. In addition, although the Company may be eligible for a further extension of up to 180 calendar days to return to compliance with continued listing requirements, such extensions are contingent on the absence of any other deficiencies. As with the MFPHS deficiency, the Company may consider applying to transfer its securities to Nasdaq Capital Market to address the MVLS deficiency.

The Company’s business operations are not affected by the receipt of the Notification Letter. The Company intends to monitor its market value between now and July 18, 2022.

About AnPac Bio

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 150 issued patents as of September 30, 2021. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 43,980 clinical samples as of September 30, 2021. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.

For more information, please visit: https://www.Anpacbio.com .

For investor and media inquiries, please contact:
Company:
Phil Case, Marketing and Investor Relations
Phone: +1-267-810-6776 (US)
Email: phil_case@AnPacbio.com

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company’s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “target,” “aim,” “predict,” “outlook,” “seek,” “goal” “objective,” “assume,” “contemplate,” “continue,” “positioned,” “forecast,” “likely,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals and registration certificates from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; our relationship with our major business partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on the economic conditions and financial markets and our business and financial performance, such as resulting from reduced commercial activities due to quarantines and travel restrictions instituted by China, the U.S. and many other countries around the world to contain the spread of the virus. Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

 

Monday, January 24th, 2022 News No Comments